StockStory
2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky
➖
AI Sentiment
Neutral
5/10
- Home
- VRTX
as of 12-22-2025 3:32pm EST
$457.11
+$1.69
+0.37%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Chart Type:
Time Range:
| Founded: | 1989 | Country: | United States |
| Employees: | 6100 | City: | BOSTON |
| Market Cap: | 115.7B | IPO Year: | 1991 |
| Target Price: | $494.64 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 14.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $362.50 - $519.68 | Next Earning Date: | 02-09-2026 |
| Revenue: | $11,723,300,000 | Revenue Growth: | 10.33% |
| Revenue Growth (this year): | 11.01% | Revenue Growth (next year): | 8.74% |
AI-Powered VRTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.79%
72.79%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
Tatsis Ourania
Sell
EVP, Chief Reg. & Quality Off.
VRTX Dec 3, 2025
Avg Cost/Share
$449.99
Shares
4,500
Total Value
$2,024,955.00
Owned After
46,793
SEC Form 4
LEIDEN JEFFREY M
Sell
Executive Chairman
VRTX Dec 3, 2025
Avg Cost/Share
$447.70
Shares
63,781
Total Value
$28,650,336.65
Owned After
52,137
Biller Jonathan
Sell
EVP and Chief Legal Officer
VRTX Dec 3, 2025
Avg Cost/Share
$449.00
Shares
347
Total Value
$155,803.00
Owned After
15,306
SEC Form 4
WAGNER CHARLES F JR
Sell
EVP, CO & FO
VRTX Dec 3, 2025
Avg Cost/Share
$456.00
Shares
14,000
Total Value
$6,384,000.00
Owned After
37,725
Atkinson Edward Morrow III
Sell
EVP, Chief Technical Ops. Off.
VRTX Nov 17, 2025
Avg Cost/Share
$434.58
Shares
2,500
Total Value
$1,086,450.00
Owned After
16,852
SEC Form 4
LEIDEN JEFFREY M
Sell
Executive Chairman
VRTX Nov 14, 2025
Avg Cost/Share
$441.22
Shares
53,604
Total Value
$23,624,305.70
Owned After
52,137
LEIDEN JEFFREY M
Sell
Executive Chairman
VRTX Nov 13, 2025
Avg Cost/Share
$440.64
Shares
19,688
Total Value
$8,668,014.16
Owned After
52,137
Biller Jonathan
Sell
EVP and Chief Legal Officer
VRTX Oct 2, 2025
Avg Cost/Share
$404.21
Shares
694
Total Value
$280,521.74
Owned After
15,306
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Dec 3, 2025 | Sell | $449.99 | 4,500 | $2,024,955.00 | 46,793 | |
| LEIDEN JEFFREY M | VRTX | Executive Chairman | Dec 3, 2025 | Sell | $447.70 | 63,781 | $28,650,336.65 | 52,137 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Dec 3, 2025 | Sell | $449.00 | 347 | $155,803.00 | 15,306 | |
| WAGNER CHARLES F JR | VRTX | EVP, CO & FO | Dec 3, 2025 | Sell | $456.00 | 14,000 | $6,384,000.00 | 37,725 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Nov 17, 2025 | Sell | $434.58 | 2,500 | $1,086,450.00 | 16,852 | |
| LEIDEN JEFFREY M | VRTX | Executive Chairman | Nov 14, 2025 | Sell | $441.22 | 53,604 | $23,624,305.70 | 52,137 | |
| LEIDEN JEFFREY M | VRTX | Executive Chairman | Nov 13, 2025 | Sell | $440.64 | 19,688 | $8,668,014.16 | 52,137 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Oct 2, 2025 | Sell | $404.21 | 694 | $280,521.74 | 15,306 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Zacks
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
📈
AI Sentiment
Highly Positive
8/10
Compare VRTX vs Leading Stocks
See how VRTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.